Wednesday, October 1, 2025

Beware of the "Normal" Troponin

Beware of the "Normal" Troponin: A Critical Care Perspective

Dr Neeraj Manikath , claude.ai

Abstract

Cardiac troponins have revolutionized the diagnosis of myocardial injury, yet their interpretation remains fraught with clinical pitfalls. A "normal" troponin does not always exclude acute coronary syndrome (ACS), and clinicians must understand the temporal dynamics of troponin release, the limitations of assay sensitivity, and clinical scenarios where troponin levels may be falsely reassuring. This review addresses critical questions facing intensivists and emergency physicians: when should troponin testing be repeated, and in which conditions might troponin levels be misleadingly low? Understanding these nuances is essential for preventing diagnostic errors that can prove fatal.

Keywords: Troponin, acute coronary syndrome, myocardial infarction, high-sensitivity troponin, diagnostic timing

Introduction

Cardiac troponins (cTnI and cTnT) are the cornerstone biomarkers for diagnosing acute myocardial infarction (AMI). Their exquisite cardiac specificity and sensitivity have made them indispensable in modern cardiology and critical care practice.1,2 However, the mantra "troponin rules out MI" represents dangerous oversimplification. A single normal troponin value can provide false reassurance, potentially leading to premature discharge of patients with evolving myocardial infarction or missed diagnoses in specific clinical contexts.

The transition from conventional troponin assays to high-sensitivity troponin (hs-cTn) assays has improved early detection but has also introduced new interpretive challenges.3 This review focuses on two critical clinical scenarios that every intensivist must master: determining optimal timing for repeat troponin testing and recognizing conditions where troponin may be falsely low or undetectable despite genuine myocardial ischemia.

The Biology of Troponin Release: Understanding the Timeline

Kinetics of Troponin Elevation

Following acute myocardial injury, troponin begins appearing in peripheral blood within 2-4 hours, peaks at 12-24 hours, and may remain elevated for 7-14 days.4,5 However, this timeline represents average behavior and exhibits significant individual variation based on:

Infarct size: Larger infarcts produce earlier and higher peaks
Reperfusion status: Successful reperfusion accelerates troponin washout, causing earlier and higher peaks6
Collateral circulation: May delay or blunt troponin rise
Assay sensitivity: High-sensitivity assays detect elevations earlier than conventional assays7

The "Troponin-Negative" Window

The most dangerous period is the first 2-4 hours after symptom onset, when troponin levels may remain within normal limits despite ongoing myocardial infarction. Studies demonstrate that approximately 10-15% of patients with AMI present within this "troponin-negative window."8,9 This represents the primary rationale for serial troponin testing.

Pearl #1: Never discharge a patient with suspected ACS based on a single troponin drawn within 3 hours of symptom onset, regardless of assay sensitivity.

When to Repeat Troponin Testing

Evidence-Based Protocols

Conventional Troponin Assays

With conventional assays, the standard approach requires:

Baseline troponin at presentation
Repeat testing at 6-12 hours after symptom onset10,11
Additional testing at 12-24 hours if clinical suspicion remains high

High-Sensitivity Troponin Assays

The advent of hs-cTn assays has enabled accelerated diagnostic protocols:12,13

0/1-Hour Protocol (ESC Guidelines):14

Baseline hs-cTn at presentation
Repeat at 1 hour
Rule-out criteria: Both values below assay-specific cutoffs AND absolute change <5 ng/L
Rule-in criteria: Baseline >5× URL OR absolute change ≥20% and baseline elevated

0/2-Hour Protocol (Alternative):15

Baseline and 2-hour testing
Provides slightly higher sensitivity for presentations very early after symptom onset
May be preferred when presentation time is uncertain

0/3-Hour Protocol (ACEP Guidelines):16

More conservative approach
Baseline and 3-hour testing
Reduces false-negative rate when symptom onset timing is unclear

Clinical Scenarios Requiring Extended Serial Testing

1. Delayed Presentation

Patients presenting >24 hours after symptom onset may have passed the peak troponin window. Consider:

Troponin at presentation and 6 hours later
Look for downward trend (suggesting peak has passed)
Correlate with ECG evolution and imaging findings17

2. Stutter Symptoms

Patients with stuttering chest pain over hours to days:

Each symptomatic episode may represent a separate ischemic event
Repeat troponin 3-6 hours after each significant symptomatic episode18
Rising or persistently elevated troponins suggest ongoing injury

3. High-Risk Features Despite Normal Initial Troponin

Dynamic ECG changes (even if non-diagnostic)
Hemodynamic instability
High-risk clinical features (GRACE score >140)19
History of proven coronary artery disease
Action: Repeat troponin at 3-6 hours AND consider provocative testing or imaging

4. Renal Dysfunction

Chronic kidney disease (CKD) creates interpretive challenges:

Chronically elevated baseline troponins are common in CKD20
Rising or falling pattern (delta change) becomes more important than absolute values
Consider repeat testing at 6 hours with attention to:
- Absolute change >20% suggests acute injury21
- Stable chronic elevation suggests chronic myocardial injury or strain

Pearl #2: In patients with CKD and chronically elevated troponin, obtain baseline values during stable periods to establish individual "normal" for comparison during acute presentations.

5. Clinical-Laboratory Discordance

When clinical picture strongly suggests ACS but initial troponin is normal:

Repeat at 3 and 6 hours minimum
Do not rely solely on biomarkers—integrate clinical assessment, ECG, and imaging22
Consider immediate invasive or non-invasive imaging if very high suspicion

Oyster #1: A patient with ongoing chest pain, dynamic ST-segment changes, and "normal" troponin likely has sampling during the troponin-negative window or severe stenosis with intermittent ischemia. Do NOT wait for troponin elevation to act—these patients need urgent angiography.

Conditions Where Troponin May Be Falsely Low

1. Very Early Presentation (The Classic Pitfall)

Mechanism: Insufficient time for troponin to leak from injured cardiomyocytes into circulation

Clinical Context:

Patients presenting within 2-4 hours of symptom onset23
More problematic with conventional assays than hs-cTn assays
Even hs-cTn may be negative in first 1-2 hours in 5-10% of AMI patients24

Management Strategy:

Mandatory serial testing
Consider copeptin (if available) to improve early rule-out25
Rely heavily on clinical assessment and ECG findings
Low threshold for provocative testing or coronary CT angiography

Hack #1: In the first 3 hours after symptom onset, the ECG is actually MORE sensitive than troponin. Trust dynamic ECG changes over a single troponin value.

2. Small Infarcts and Microinfarctions

Mechanism: Limited myocardial necrosis producing troponin quantities below detection threshold

Clinical Context:

Distal vessel occlusions or small branch occlusions
Spontaneously reperfused STEMI with limited infarct size26
Microembolization during ACS or procedures
Early reperfusion limiting infarct size

Diagnostic Clues:

Regional wall motion abnormalities on echocardiography disproportionate to troponin level
New Q waves or T-wave inversions on ECG
Perfusion defects on nuclear imaging or cardiac MRI showing late gadolinium enhancement27

Management Strategy:

Do not dismiss ACS based solely on "negative" troponin if imaging shows infarction
Cardiac MRI is gold standard for detecting small infarcts28
Treat according to clinical syndrome, not biomarker levels alone

Pearl #3: Cardiac MRI can detect myocardial infarction as small as 1 gram of myocardium, well below the threshold for troponin detection.

3. Severe Proximal Coronary Occlusion (The Paradox)

Mechanism: Complete occlusion preventing troponin washout into circulation; the "stone heart" phenomenon

Clinical Context:

Acute complete occlusion of left main or proximal LAD
Cardiogenic shock with severely reduced cardiac output
Sudden cardiac death with successful resuscitation29

Clinical Features:

Profound hemodynamic compromise
Extensive ST-segment elevation
Rapidly evolving cardiogenic shock
Troponin may be normal or only minimally elevated initially

Pathophysiology: This counterintuitive scenario occurs because:

Complete occlusion prevents antegrade flow that would wash troponin into circulation
Severely reduced cardiac output limits biomarker distribution
Microvascular obstruction prevents troponin release30

Management Strategy:

Emergency angiography should NOT wait for troponin elevation
Clinical presentation and ECG findings take precedence
After revascularization, expect dramatic troponin surge

Oyster #2: The sickest MI patients may have the lowest initial troponins. If a patient is in cardiogenic shock with STEMI, don't wait for troponin confirmation—get them to the cath lab immediately.

4. Takotsubo Cardiomyopathy (Stress Cardiomyopathy)

Mechanism: Myocardial stunning without significant necrosis

Clinical Context:

Presents identically to acute MI (chest pain, dyspnea, ECG changes)
Triggered by emotional or physical stress31
Predominantly affects postmenopausal women
Characteristic apical ballooning on ventriculography

Troponin Patterns:

Usually elevated, but elevation is modest relative to extent of wall motion abnormality32
Peak troponin typically lower than expected for degree of LV dysfunction
Troponin may be normal in up to 10% of cases despite significant stunning33

Diagnostic Features:

Dramatic wall motion abnormalities extending beyond single coronary distribution
ECG changes (ST elevation or deep T wave inversions)
Normal or non-obstructive coronary arteries on angiography
Disproportionately low troponin for extent of dysfunction

Management Strategy:

Requires angiography to exclude coronary occlusion
Supportive care; usually complete recovery
Mimics acute MI closely—cannot reliably distinguish before angiography

Hack #2: If BNP/NT-proBNP is dramatically elevated (>10,000 pg/mL) but troponin is only mildly elevated, think Takotsubo over STEMI.

5. Reperfusion Before Testing

Mechanism: Spontaneous reperfusion or successful pre-hospital treatment limiting infarct size

Clinical Context:

Patients with spontaneous lysis of thrombus
Pre-hospital thrombolysis or antiplatelet/anticoagulant therapy
Intermittent coronary vasospasm (Prinzmetal's angina)34

Clinical Features:

Resolution of chest pain before ED arrival
ECG normalization or significant improvement
Normal or minimally elevated troponin at presentation
May have regional wall motion abnormalities on echo despite normal troponin

Management Strategy:

High index of suspicion for "aborted MI"
Proceed to angiography based on clinical presentation
Serial troponins may show late rise as necrotic myocardium releases remaining troponin
Cardiac MRI may reveal small areas of infarction35

Pearl #4: Pain resolution and ECG normalization do NOT exclude MI. These findings may indicate successful reperfusion, but the patient still needs risk stratification and likely angiography.

6. Assay Interference (Rare but Important)

Mechanism: Technical factors producing falsely low measurements

Causes:

Heterophile antibodies: Human anti-mouse antibodies (HAMA) interfering with immunoassays36
Biotin interference: High-dose biotin supplementation interfering with troponin assays using biotin-streptavidin technology37
Hemolysis: Can falsely lower cTnI in some assays (though usually causes falsely elevated results)38
Fibrin clots: Incomplete clotting may lead to falsely low results

Clinical Clues:

Clinical picture strongly suggestive of MI with unexpectedly normal troponin
Known use of biotin supplements (increasingly common)
Recent exposure to mouse proteins (unlikely in most settings)
Visibly hemolyzed samples

Management Strategy:

Repeat testing with new sample if interference suspected
Test on different analyzer platform if available
Stop biotin supplementation 72 hours before testing if possible
Ensure proper sample collection and handling

Hack #3: Always ask about supplement use, particularly biotin. Patients taking high-dose biotin (often for hair/nail health) may have falsely low troponin results.

7. Extreme Hemodilution

Mechanism: Dilutional effect lowering troponin concentration below detection threshold

Clinical Context:

Massive volume resuscitation
Extracorporeal membrane oxygenation (ECMO) initiation39
Continuous renal replacement therapy (CRRT) initiation
Post-cardiac surgery with massive transfusion

Clinical Features:

Temporally related to massive fluid administration
Other biomarkers also diluted (BNP, lactate, hemoglobin all decrease)
Clinical signs of fluid overload

Management Strategy:

Consider dilutional effect when interpreting all biomarkers
Correlate with clinical context and timing of resuscitation
May need higher index of suspicion for MI during massive resuscitation
Use imaging modalities (echo, cardiac MRI) when troponin unreliable

8. Coronary Vasospasm Without Infarction

Mechanism: Transient ischemia without sufficient myocyte necrosis to release detectable troponin

Clinical Context:

Prinzmetal's (variant) angina
Cocaine-associated chest pain40
Vasospastic angina in young women
Drug-induced vasospasm (amphetamines, ergotamines)

Clinical Features:

Typical anginal symptoms, often at rest or early morning
Transient ST-segment elevation during pain
Normal coronaries or minimal CAD on angiography
Positive provocative testing (acetylcholine, ergonovine)41

Troponin Patterns:

Usually normal unless vasospasm causes infarction
Prolonged vasospasm can lead to infarction with troponin elevation
Serial troponins may remain normal despite recurrent symptoms

Management Strategy:

Diagnosis requires high clinical suspicion
Provocative testing in cath lab for definitive diagnosis
Calcium channel blockers and nitrates for treatment
Avoid beta-blockers (may worsen vasospasm)

Pearl #5: ST elevation that resolves spontaneously with sublingual nitroglycerin suggests vasospasm. These patients need coronary angiography with provocative testing, not just troponin surveillance.

9. Chronic Total Occlusion with Established Collaterals

Mechanism: Well-developed collateral circulation preventing ischemia despite total occlusion

Clinical Context:

Patients with long-standing CAD
Gradual vessel occlusion allowing collateral development
May present with stable angina or be asymptomatic42

Clinical Features:

Minimal or no symptoms despite angiographic total occlusion
ECG may show old Q waves but no acute changes
Normal troponin despite severe anatomic disease
Viable myocardium supplied by collaterals

Management Strategy:

These patients are NOT having acute MI despite severe CAD
CTO revascularization is elective decision based on symptoms and ischemia burden
Normal troponin correctly reflects absence of acute injury

10. Demand Ischemia Without Type 1 MI

Mechanism: Supply-demand mismatch without atherosclerotic plaque rupture

Clinical Context:

Type 2 MI: severe anemia, hypotension, tachyarrhythmias, hypertensive emergency43
Severe sepsis or septic shock
Hypoxemic respiratory failure
Hypertrophic cardiomyopathy with dynamic obstruction

Troponin Patterns:

May be normal or elevated depending on duration and severity
When elevated, typically modest rise compared to Type 1 MI
Rise and fall kinetics may be slower than Type 1 MI44

Diagnostic Considerations:

Normal troponin doesn't exclude demand ischemia (may not cause necrosis)
ECG changes may be present without troponin elevation
Treatment focuses on correcting underlying cause

Oyster #3: Septic patients with troponin elevation have worse outcomes, but this usually represents septic cardiomyopathy or demand ischemia, not acute coronary occlusion. Don't rush them to the cath lab—optimize their hemodynamics.

Practical Approach: Clinical Decision-Making Framework

Step 1: Assess Pre-Test Probability

Use validated risk scores:

HEART Score: Useful for ED risk stratification45
GRACE Score: For confirmed ACS prognostication46
TIMI Risk Score: Alternative validated tool47

Step 2: Determine Optimal Troponin Strategy

High Pre-Test Probability (HEART ≥4):

Serial troponins mandatory regardless of initial value
Low threshold for urgent angiography if ECG concerning
Do not delay management for troponin results if STEMI or equivalent

Moderate Pre-Test Probability (HEART 3):

Use accelerated protocol (0/1h or 0/3h depending on assay)
If rule-out criteria met, consider stress testing before discharge
If rule-in criteria met, proceed to early invasive strategy

Low Pre-Test Probability (HEART 0-2):

Single troponin may suffice if hs-cTn assay used and presentation >3h from symptom onset
Consider alternative diagnoses
Consider stress testing for definitive exclusion if any doubt

Step 3: Recognize Red Flags for Falsely Low Troponin

Clinical Red Flags:

Presentation within 3 hours of symptom onset
Dynamic ECG changes despite normal troponin
Cardiogenic shock with minimal troponin elevation
Clinical picture highly suggestive of ACS
Known biotin supplementation

Action Plan:

Do not rely on single troponin value
Employ imaging (echo, CT coronary angiography, cardiac MRI)
Consider urgent/emergent angiography based on clinical picture
Remember: ECG and clinical assessment trump biomarkers in the first 3 hours

Step 4: Integrate Multi-Modal Assessment

Never rely on troponin alone. Integrate:

Clinical presentation (quality of pain, associated symptoms, risk factors)
Serial ECGs (perform every 10-15 minutes if ongoing pain)
Echocardiography (regional wall motion abnormalities precede troponin rise)
Advanced imaging when indicated (coronary CTA, cardiac MRI, nuclear imaging)

Special Populations and Scenarios

The Critically Ill Patient

Challenges:

Multiple confounders (sepsis, shock, renal failure, vasopressors)
Difficulty distinguishing Type 1 from Type 2 MI48
Limited ability to communicate symptoms
Hemodynamic instability limiting imaging options

Approach:

Serial troponins every 6-12 hours during critical illness
Trend troponin levels (rising, falling, or stable plateau)
Integrate bedside echo findings
Rising troponin with new wall motion abnormalities suggests Type 1 MI
Consider angiography if Type 1 MI suspected despite elevated baseline troponins

Hack #4: In the ICU patient with chronically elevated troponin, a rising trend + new regional wall motion abnormality on echo = Type 1 MI until proven otherwise.

Post-Cardiac Surgery

Challenges:

Troponin universally elevated after cardiac surgery49
Distinguishing expected post-operative rise from perioperative MI
Variable kinetics based on surgical technique and ischemic time

Troponin Patterns:

Expected rise: Peak at 12-24 hours post-op, then steady decline
Perioperative MI: Persistent elevation or secondary rise after initial decline50
Thresholds: >10× URL at 48 hours suggests significant perioperative MI

Diagnostic Approach:

Baseline troponin pre-operatively if possible
Serial post-operative troponins (6h, 12h, 24h, 48h)
New Q waves or persistent ST-segment changes suggest MI
Echo showing new regional wall motion abnormality
Rising troponin after initial decline is concerning

Cardiac Arrest Survivors

Challenges:

Global ischemia during arrest elevates troponin
Distinguishing primary cardiac cause from arrest-induced elevation51
Post-arrest myocardial stunning confounds assessment

Troponin Patterns:

Elevated in >90% of cardiac arrest survivors regardless of etiology
Very high levels (>10× URL) suggest primary cardiac cause
Kinetics may be delayed due to low-flow state

Diagnostic Strategy:

Do not exclude coronary cause based on normal initial troponin
Urgent angiography for all STEMI-equivalent post-arrest ECGs
Consider early angiography for non-diagnostic ECGs with high suspicion52
Serial troponins less useful than ECG and emergent coronary angiography

Emerging Technologies and Future Directions

Point-of-Care High-Sensitivity Troponin

Rapid turnaround time enabling faster rule-in/rule-out53
Comparable performance to central laboratory assays
May facilitate emergency department workflow

Novel Biomarkers

Copeptin: Improves early rule-out when combined with troponin54
Heart-type fatty acid binding protein (H-FABP): Earlier release than troponin55
MicroRNAs: Experimental but promising for very early detection56

Artificial Intelligence Integration

Machine learning algorithms combining clinical, ECG, and biomarker data
May improve risk stratification beyond individual parameters57
Validation in diverse populations ongoing

Key Clinical Pearls Summary

Pearl #1: Never discharge based on single troponin within 3 hours of symptom onset

Pearl #2: Establish baseline troponin in CKD patients during stable periods for acute comparison

Pearl #3: Cardiac MRI detects infarcts too small for troponin detection

Pearl #4: Pain resolution and ECG normalization don't exclude MI—may indicate reperfusion

Pearl #5: ST elevation resolving with nitroglycerin suggests vasospasm—needs provocative testing

Key Oysters (Unexpected Findings)

Oyster #1: Dynamic ECG changes with normal troponin need urgent angiography, not troponin surveillance

Oyster #2: Sickest MI patients (cardiogenic shock) may have lowest initial troponins

Oyster #3: Septic patients with elevated troponin rarely need cath lab—optimize hemodynamics first

Clinical Hacks

Hack #1: In first 3 hours, ECG is MORE sensitive than troponin—trust dynamic ECG changes

Hack #2: BNP >>10,000 with mild troponin elevation suggests Takotsubo over STEMI

Hack #3: Always ask about biotin supplements—can falsely lower troponin

Hack #4: ICU patient with rising troponin + new wall motion abnormality = Type 1 MI until proven otherwise

Conclusions

The "normal" troponin represents a common clinical pitfall with potentially fatal consequences. Clinicians must understand the temporal dynamics of troponin release, recognize the limitations of early testing, and identify clinical scenarios where troponin may be falsely reassuring. Serial testing remains the cornerstone of excluding AMI, but timing must be individualized based on symptom onset, clinical features, and assay characteristics.

High-sensitivity troponin assays have improved early detection but have not eliminated the need for clinical judgment. The integration of clinical assessment, serial ECGs, biomarker kinetics, and cardiac imaging provides the most robust approach to diagnosing or excluding acute coronary syndromes. Ultimately, no single biomarker can replace careful clinical reasoning and a thorough understanding of troponin biology.

The cardinal rule: When clinical suspicion is high, do not let a "normal" troponin provide false reassurance. Trust the patient's presentation, trust dynamic ECG changes, and when in doubt, pursue definitive testing. The most dangerous troponin result is the one that stops you from thinking.

References

Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651.
Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48(1):1-11.
Sandoval Y, Apple FS. The global need to define normality: the 99th percentile value of cardiac troponin. Clin Chem. 2014;60(3):455-462.
Adams JE 3rd, Bodor GS, Dávila-Román VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation. 1993;88(1):101-106.
Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007;53(4):547-551.
Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol. 1991;67(16):1360-1367.
Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858-867.
Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol. 2011;58(13):1332-1339.
Haaf P, Drexler B, Reichlin T, et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation. 2012;126(1):31-40.
Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med. 1997;337(23):1648-1653.
Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335(18):1342-1349.
Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267-315.
Neumann JT, Twerenbold R, Ojeda F, et al. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med. 2019;380(26):2529-2540.
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367.
Mueller C, Giannitsis E, Christ M, et al. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016;68(1):76-87.
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes. Circulation. 2014;130(25):e344-e426.
Eggers KM, Jernberg T, Ljung L, et al. High-sensitivity cardiac troponin T for early diagnosis of acute myocardial infarction. J Intern Med. 2012;271(3):271-281.
Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation. 2000;102(11):1216-1220.
Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091.
Dubin RF, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol. 2013;14:229.
Twerenbold R, Jaffe A, Reichlin T, et al. High-sensitive troponin T measurements: what do we gain and what are the challenges? Eur Heart J. 2012;33(5):579-586.
Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. 2000;342(16):1163-1170.
Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868-877.
Body R, Mueller C, Giannitsis E, et al. The Use of Very Low Concentrations of High-sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Baseline Blood Test. Acad Emerg Med. 2016;23(9):1004-1013.
Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54(1):60-68.
Gibbons RJ, Valeti US, Araoz PA, et al. The quantification of infarct size. J Am Coll Cardiol. 2004;44(8):1533-1542.

Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012;33(18):2252-2257.
Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445-1453.
Mullins KE, Christenson RH. The prognostic value of cardiac troponins. Scand J Clin Lab Invest Suppl. 1999;230:130-135.
Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97(8):765-772.
Templin C, Ghadri JR, Diekmann J, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med. 2015;373(10):929-938.
Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010;55(4):333-341.
Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018;39(22):2032-2046.
Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011;124(16):1774-1782.
Abdel-Aty H, Zagrosek A, Schulz-Menger J, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation. 2004;109(20):2411-2416.
Bolstad N, Warren DJ, Nustad K. Heterophilic antibody interference in immunometric assays. Best Pract Res Clin Endocrinol Metab. 2013;27(5):647-661.
Piketty ML, Polak M, Flechtner I, et al. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med. 2017;55(6):780-788.
Lippi G, Salvagno GL, Montagnana M, et al. Influence of hemolysis on routine clinical chemistry testing. Clin Chem Lab Med. 2006;44(3):311-316.
Rupprecht L, Flörchinger B, Schopka S, et al. Cardiac surgery for patients in cardiogenic shock requiring extracorporeal membrane oxygenation--an analysis of 171 patients. Eur J Cardiothorac Surg. 2013;44(2):269-274.
Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group. Acad Emerg Med. 1994;1(4):330-339.
Ong P, Athanasiadis A, Hill S, et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. 2008;52(7):523-527.
Werner GS, Surber R, Ferrari M, et al. The functional reserve of collaterals supplying long-term chronic total coronary occlusions in patients without prior myocardial infarction. Eur Heart J. 2006;27(20):2406-2412.
Sandoval Y, Jaffe AS. Type 2 Myocardial Infarction: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(14):1846-1860.
Saaby L, Poulsen TS, Hosbond S, et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med. 2013;126(9):789-797.
Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J. 2008;16(6):191-196.
Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345-2353.
Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-842.
Lim W, Qushmaq I, Devereaux PJ, et al. Elevated cardiac troponin measurements in critically ill patients. Arch Intern Med. 2006;166(22):2446-2454.
Muehlschlegel JD, Perry TE, Liu KY, et al. Troponin is superior to electrocardiogram and creatinine kinase MB for predicting clinically significant myocardial injury after coronary artery bypass grafting. Eur Heart J. 2009;30(13):1574-1583.
Thielmann M, Massoudy P, Jaeger BR, et al. Emergency re-revascularization with percutaneous coronary intervention, reoperation, or conservative treatment in patients with acute perioperative graft failure following coronary artery bypass surgery. Eur J Cardiothorac Surg. 2006;30(1):117-125.
Mullner M, Oschatz E, Sterz F, et al. The influence of chest compressions and external defibrillation on the release of creatine kinase-MB and cardiac troponin T in patients resuscitated from out-of-hospital cardiac arrest. Resuscitation. 1998;38(2):99-105.
Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv. 2010;3(3):200-207.
Apple FS, Sandoval Y, Jaffe AS, et al. Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care. Clin Chem. 2017;63(1):73-81.
Mockel M, Searle J, Muller R, et al. Chief complaints in medical emergencies: do they relate to underlying disease and outcome? The Charite Emergency Medicine Study (CHARITEM). Eur J Emerg Med. 2013;20(2):103-108.
O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006;114(6):550-557.
D'Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31(22):2765-2773.
Shouval R, Hadanny A, Shlomo N, et al. Machine learning for prediction of 30-day mortality after ST elevation myocardial infarction: An Acute Coronary Syndrome Israeli Survey data mining study. Int J Cardiol. 2017;246:7-13.

Supplementary Case Vignettes for Teaching

Case 1: The Very Early Presentation

Presentation: A 58-year-old man with hypertension and hyperlipidemia presents with crushing substernal chest pain that began 90 minutes ago while shoveling snow. Pain radiates to left arm, associated with diaphoresis.

Initial Evaluation:

Troponin I: 0.02 ng/mL (normal <0.04 ng/mL)
ECG: Subtle ST depression in V4-V6
Vital signs: BP 160/95, HR 98

Junior Resident's Plan: "Troponin is normal, let's observe and recheck in 6 hours."

Critical Care Pearl: This is the classic "troponin-negative window." The patient presented only 90 minutes after symptom onset—far too early for troponin to reliably exclude MI. The subtle ECG changes are concerning.

Correct Management:

Immediate aspirin, ticagrelor, anticoagulation
Repeat troponin at 3 hours (4.5 hours from symptom onset)
Continuous monitoring with serial ECGs
Low threshold for urgent angiography if ECG evolves or pain persists

Outcome: Repeat troponin at 3 hours was 2.8 ng/mL. Emergent angiography revealed 95% proximal LAD stenosis with visible thrombus. Successful PCI performed.

Teaching Point: Time from symptom onset matters more than the troponin value in the first 3 hours. Trust the clinical picture and ECG changes.

Case 2: The Shock Patient with "Low" Troponin

Presentation: A 62-year-old woman brought in by EMS with sudden onset chest pain, now in cardiogenic shock.

Initial Evaluation:

Troponin T: 0.15 ng/mL (mildly elevated; normal <0.01 ng/mL)
ECG: Anterolateral ST elevation (3-4 mm in V2-V6)
Vital signs: BP 75/50, HR 115, requiring norepinephrine
Echo: Severe global hypokinesis, EF 20%

Medical Student Question: "The troponin is only slightly elevated. Are we sure this is a STEMI?"

Critical Care Teaching: This is the paradox of severe proximal occlusion. The patient is in cardiogenic shock with massive STEMI, yet troponin is barely elevated because:

Complete occlusion prevents troponin washout into circulation
Severely reduced cardiac output limits biomarker distribution
No time has elapsed for significant troponin release

Correct Management:

Activate cath lab IMMEDIATELY—do NOT wait for troponin to rise
Mechanical circulatory support (consider Impella or IABP)
Emergent PCI

Outcome: Left main occlusion found. After PCI and Impella support, troponin peaked at 187 ng/mL at 24 hours—but initial low level almost caused dangerous delay.

Teaching Point: The sickest MI patients may have the lowest initial troponins. STEMI diagnosis is clinical and electrocardiographic—troponin confirmation is not required for cath lab activation.

Case 3: The Biotin Interference

Presentation: A 45-year-old woman with chest pain, presented 8 hours after symptom onset.

Initial Evaluation:

Troponin I: Undetectable (<0.01 ng/mL)
ECG: T wave inversions in inferior leads
Echo: Hypokinesis of inferior wall

Cardiologist: "This doesn't make sense. Echo shows acute injury but troponin is undetectable 8 hours out. Let's repeat on a different analyzer."

Second troponin (different platform): 8.5 ng/mL—clearly elevated

Investigation: Patient was taking 10,000 mcg/day of biotin for hair and nail health. First assay used biotin-streptavidin technology, which was subject to biotin interference causing falsely low results.

Critical Care Pearl: Always ask about supplements. High-dose biotin supplementation is increasingly common and can cause falsely low troponin results on certain assay platforms.

Teaching Point: Assay interference is rare but important. When clinical picture and biomarkers don't align, consider technical factors and repeat testing.

Case 4: The CKD Patient with Chronic Elevation

Presentation: A 70-year-old man with ESRD on hemodialysis presents with chest pain.

Initial Evaluation:

Troponin T: 0.18 ng/mL (his baseline is typically 0.15-0.20 ng/mL)
ECG: Non-specific changes, unchanged from prior
No dialysis for 3 days (missed sessions)

Emergency Physician: "His troponin is elevated, so we're admitting for NSTEMI."

Nephrologist: "Wait—check his baseline. He's always elevated due to CKD."

Critical Management Decision:

Obtained troponin from 2 months ago during routine labs: 0.16 ng/mL
Current level (0.18 ng/mL) represents only 12.5% change—within normal variation
Serial troponins at 0, 3, and 6 hours: 0.18, 0.19, 0.17 ng/mL (stable)
ECG unchanged, echo unchanged from prior
Diagnosis: Non-cardiac chest pain in CKD patient with chronically elevated troponin

Teaching Point: In CKD patients:

Establish baseline troponin during stable periods
Look for CHANGE (>20% rise or fall) rather than absolute values
Serial testing showing stability argues against acute MI
Integrate clinical picture—don't diagnose MI on troponin alone in CKD

Case 5: The Takotsubo Mimic

Presentation: A 68-year-old woman presents with chest pain one hour after learning of her husband's sudden death.

Initial Evaluation:

Troponin I: 0.85 ng/mL (mildly elevated)
ECG: Anterior ST elevation
Echo: Severe apical and mid-ventricular akinesis, EF 30%
BNP: 14,500 pg/mL

STEMI Alert Called: Patient taken emergently to cath lab

Angiogram: Normal coronary arteries—no stenosis, no thrombus

Ventriculogram: Classic apical ballooning ("octopus pot" appearance)

Critical Observation: The resident notes, "The troponin seems low for that degree of LV dysfunction—the entire apex isn't moving!"

Diagnosis: Takotsubo (stress) cardiomyopathy

Teaching Points:

Troponin in Takotsubo is typically elevated but modest relative to degree of dysfunction
Very high BNP with relatively low troponin is a clue
Emotional stressor in postmenopausal woman is classic
Angiography required to confirm diagnosis (can't distinguish from MI clinically)
Management is supportive; usually complete recovery

Summary Algorithm: When to Worry About "Normal" Troponin

Patient with suspected ACS and normal troponin
                    ↓
    ┌───────────────┴───────────────┐
    ↓                               ↓
Presentation <3 hours          Presentation ≥3 hours
from symptom onset             from symptom onset
    ↓                               ↓
HIGH RISK                      Check clinical features
• Mandatory serial testing     • ECG changes?
• Do not exclude MI           • High-risk features?
• ECG findings trump troponin  • HEART score ≥4?
• Low threshold for cath lab   ↓
                              ┌─┴─┐
                              ↓   ↓
                            YES  NO
                              ↓   ↓
                         Serial testing  Consider single
                         required       troponin sufficient
                                       (if hs-cTn used)

Red Flags Requiring Serial Testing Regardless:

Dynamic ECG changes
Ongoing chest pain
Hemodynamic instability
Known CAD with typical symptoms
Diabetes with anginal equivalent
GRACE score >140

Final Thought: A Philosophy of Troponin Interpretation

Troponin is an extraordinarily powerful biomarker, but it is not infallible. The best clinicians understand that troponin must be interpreted within the context of:

Time: When was blood drawn relative to symptom onset?
Trend: Is this a single value or part of a serial pattern?
Clinical context: Does the troponin result fit the clinical picture?
ECG findings: Do electrical changes support or contradict the biomarker?
Imaging: What does direct visualization of the myocardium show?

The "normal" troponin can be the most dangerous laboratory result if it creates false reassurance. Conversely, an elevated troponin without clinical correlation can trigger unnecessary interventions. The art of medicine lies in synthesizing all available data into a coherent clinical picture.

Remember: You are treating the patient, not the laboratory value. When in doubt, serial testing, imaging, and direct visualization (angiography) provide definitive answers. The patient with ongoing chest pain and dynamic ECG changes deserves aggressive evaluation regardless of initial troponin values.

As Sir William Osler famously stated, "Listen to your patient; he is telling you the diagnosis." In the era of high-sensitivity troponins, we might add: "But don't let a single laboratory value override what your patient—and their ECG—are telling you."

Abstract

Diarrhea affects 15-38% of critically ill patients and represents a significant challenge in intensive care management. While Clostridioides difficile infection dominates clinical concern, the majority of ICU diarrhea cases have non-infectious etiologies. This review examines the multifactorial nature of ICU-associated diarrhea, with emphasis on antibiotic-associated diarrhea, enteral nutrition complications, and medication-related causes. We provide evidence-based guidance on diagnostic stewardship, highlighting when testing is indicated versus when empirical management is appropriate. Understanding the diverse etiologies and implementing rational diagnostic approaches can reduce unnecessary testing, prevent inappropriate antibiotic escalation, and improve patient outcomes.

Keywords: Diarrhea, intensive care unit, Clostridioides difficile, enteral nutrition, antibiotic-associated diarrhea, diagnostic stewardship

Introduction

Diarrhea in the intensive care unit (ICU) is remarkably common, with reported incidence ranging from 15% to 38% of all critically ill patients and up to 60% in specific populations receiving enteral nutrition.[1,2] The knee-jerk response—"test for C. difficile"—overlooks a critical reality: approximately 60-80% of ICU diarrhea has non-infectious causes.[3] This reflexive testing contributes to diagnostic uncertainty, unnecessary isolation, inappropriate antimicrobial therapy, and increased healthcare costs.

The ICU patient presents unique challenges. Multiple medications, altered gut physiology, enteral feeding protocols, and genuine infectious risks create a diagnostic labyrinth. This review synthesizes current evidence to guide clinicians through this common clinical scenario, emphasizing practical diagnostic and therapeutic approaches.

Defining Diarrhea in the ICU: More Than Meets the Eye

The definition of diarrhea in critical care lacks universal consensus. Common definitions include:

≥3 loose or watery stools per day (WHO definition)
Stool weight >200-250 g/day
Liquid stool output >200 mL/day in the presence of rectal catheter

Pearl: In ICU patients with enteral feeding, stool frequency may be misleading. Focus on stool consistency using the Bristol Stool Scale (Types 6-7) and volume rather than frequency alone.[4]

Oyster: Fecal incontinence is not diarrhea. Many ICU patients labeled as having "diarrhea" actually have fecal incontinence from sphincter dysfunction, altered sensorium, or local anorectal pathology.

The Microbial Red Herring: Why Most ICU Diarrhea Isn't Infection

The C. difficile Conundrum

Clostridioides difficile infection (CDI) accounts for only 10-20% of ICU diarrhea cases, yet testing rates approach 50% in some centers.[5] This disconnect stems from appropriate concern given the morbidity of missed CDI, but creates several problems:

Colonization vs. Infection: Up to 20-30% of hospitalized patients become colonized with C. difficile, and colonization rates are higher in ICU populations.[6] Current nucleic acid amplification tests (NAATs) cannot distinguish colonization from infection.
Asymptomatic Shedding: Positive C. difficile toxin in asymptomatic patients or those with alternative explanations for diarrhea leads to unnecessary treatment.

Hack: Before ordering C. difficile testing, ask three questions:

Has the patient received ≥3 loose stools in 24 hours?
Are there no obvious alternative causes (see below)?
Will a positive result change management?

If the answer to any is "no," defer testing.

Non-Infectious Etiologies: The Usual Suspects

1. Antibiotic-Associated Diarrhea (Non-C. difficile)

Antibiotics alter gut microbiota, causing diarrhea in 5-25% of recipients independent of C. difficile.[7] The mechanism is multifactorial:

Direct effects on colonocyte function
Decreased carbohydrate fermentation (reduced short-chain fatty acids)
Loss of bile acid metabolism (increased colonic water secretion)
Osmotic effects from unabsorbed carbohydrates

High-Risk Antibiotics:

Clindamycin (20% incidence)
Amoxicillin-clavulanate (10-25%)
Cephalosporins (15-20%)
Fluoroquinolones (5-10%)

Time Course: Typically begins during antibiotic therapy or within 2-8 weeks after discontinuation.

Pearl: Antibiotic-associated diarrhea without C. difficile is a diagnosis of exclusion but should be high on the differential in patients with recent antibiotic exposure, negative testing, and no alarm features.

Management:

Discontinue or change antibiotics if clinically appropriate
Consider probiotic supplementation (evidence modest but Lactobacillus and Saccharomyces boulardii show some benefit)[8]
Symptomatic treatment with loperamide if no contraindications
Typically resolves within 3-7 days of antibiotic cessation

2. Enteral Nutrition: The Usual Suspect

Enteral nutrition-associated diarrhea (ENAD) affects 20-68% of tube-fed ICU patients.[9] Multiple mechanisms contribute:

A. Osmotic Diarrhea

Causes:

Hyperosmolar formulas (>400 mOsm/kg)
Medications administered via feeding tube (sorbitol-containing suspensions, magnesium, phosphate)
Rapid bolus administration

Oyster: That "innocent" medication flush? Many liquid medications contain sorbitol (70% osmolality ~3500 mOsm/kg). Common culprits include liquid acetaminophen, furosemide, and some antibiotic suspensions.[10]

Hack: Calculate total sorbitol load. >10-20g/day frequently causes osmotic diarrhea. Review all medications administered via tube and substitute sorbitol-free alternatives.

B. Malabsorption

Mechanisms:

Critical illness-induced enteropathy (villous atrophy, increased permeability)
Pancreatic insufficiency
Bile salt malabsorption
Small intestinal bacterial overgrowth (SIBO)

C. Formula-Related Factors

Fiber content: Paradoxically, both excessive and inadequate fiber can cause diarrhea
Rate and volume: Rapid advancement or excessive volumes overwhelm absorptive capacity
Temperature: Cold formulas may increase intestinal motility
Contamination: Though rare with modern closed systems

D. Gastroparesis and Intolerance

Delayed gastric emptying with small bowel dumping creates a bolus effect.

Diagnostic Approach for ENAD:

Check gastric residual volumes (though evidence for routine checking is weak)[11]
Measure stool osmotic gap:
- Osmotic gap = 290 - 2([Na+] + [K+]) in stool water
- Gap >125 mOsm/kg suggests osmotic diarrhea
- Gap <50 mOsm/kg suggests secretory diarrhea
Review feeding regimen: rate, formula osmolality, advancement schedule
Audit ALL medications administered via feeding tube

Management Strategies:

Reduce rate: Consider continuous rather than bolus feeding
Change formula:
- Try iso-osmolar formula (300 mOsm/kg)
- Consider peptide-based or elemental formulas for malabsorption
- Adjust fiber content (soluble fiber 10-15g/day may help)
Post-pyloric feeding: If gastroparesis suspected
Probiotics: Meta-analyses show modest benefit (NNT ~12 to prevent one case of diarrhea)[12]
Medication review: Eliminate unnecessary medications; use sorbitol-free alternatives

Pearl: Don't stop enteral nutrition prematurely. Up to 50% of "feeding intolerance" resolves with simple rate adjustments. The harms of prolonged nil-per-os status (gut atrophy, bacterial translocation, malnutrition) often exceed the nuisance of diarrhea.

3. Medications: Beyond Antibiotics

The ICU medication list is a veritable compendium of diarrheal triggers.

Common Offenders:

Prokinetics:

Metoclopramide (10-30% incidence)
Erythromycin (20-35%)

Cardiovascular Drugs:

Digitalis
Beta-blockers
ACE inhibitors
Antiarrhythmics (quinidine, flecainide)

Magnesium and Phosphate:

Therapeutic or nutritional supplementation
Check serum levels and reduce if elevated

Laxatives:

Osmotic agents: Lactulose, polyethylene glycol, magnesium citrate
Stimulants: Senna, bisacodyl
Stool softeners: Docusate (though weak evidence for causing diarrhea)

Oyster: The patient with hepatic encephalopathy on high-dose lactulose doesn't have "refractory encephalopathy"—they have lactulose overdose. Target 2-3 soft stools daily, not 8-10 liquid stools.

Immunosuppressants:

Mycophenolate mofetil (30-50% incidence)
Tacrolimus
mTOR inhibitors

Chemotherapy:

Irinotecan, 5-fluorouracil, tyrosine kinase inhibitors

Other:

Colchicine
NSAIDs
PPIs (via gut dysbiosis)[13]
Selective serotonin reuptake inhibitors

Management: Review medication list systematically. Discontinue non-essential medications. Adjust doses of essential medications if possible.

4. Critical Illness-Induced Factors

Sepsis and Shock:

Intestinal hypoperfusion causes mucosal injury
Increased intestinal permeability
Dysbiosis
Capillary leak and intestinal edema

Organ Dysfunction:

Renal failure: Uremia-associated enteropathy
Hepatic failure: Bile salt malabsorption, portal hypertensive enteropathy
Pancreatic insufficiency: Malabsorption

Hypothyroidism/Hyperthyroidism:

Check TSH in unexplained diarrhea

Hypoalbuminemia:

<2.5 g/dL associated with intestinal edema and malabsorption

When to Test: Diagnostic Stewardship in Action

The default to "test everyone" creates more problems than it solves. A rational approach balances the need to identify treatable infections against the harms of false-positive results and opportunity costs.

Indications for C. difficile Testing

Test when:

≥3 unformed stools in 24 hours AND one or more of:
- Fever (>38°C)
- Leukocytosis (>15,000/μL) or new/worsening
- Abdominal pain/distension
- Ileus without alternative explanation
- Toxic megacolon suspected
Recent CDI in same hospitalization (within 8 weeks)
High-risk exposure (known CDI outbreak)
Immunosuppression with diarrhea

Do NOT test:

Asymptomatic patients
Formed or solid stools (type 1-5 on Bristol scale)
Patients with obvious alternative cause (e.g., started on lactulose yesterday)
Routine screening
Test-of-cure after treatment (30% remain positive for weeks)

Pearl: Many institutions have implemented "stool rejection criteria" where the lab refuses to test formed stools or inappropriate specimens. This reduces false-positive rates by 30-40%.[14]

Testing Strategy for C. difficile

Current testing approaches have evolved:

Two-step algorithm (preferred):
- Screen with glutamate dehydrogenase (GDH) or NAAT
- If positive, confirm with toxin EIA
- Only treat if toxin-positive (or high clinical suspicion with toxin-negative)
NAAT alone:
- High sensitivity but cannot distinguish colonization from infection
- Only if strict clinical criteria applied

Hack: Use validated clinical prediction tools:

Dubberke score: Age, fever, WBC, recent CDI
Helps stratify pre-test probability and reduces unnecessary testing[15]

When to Test for Other Pathogens

Bacterial Culture (Salmonella, Shigella, Campylobacter):

Diarrhea with blood or mucus
Recent travel or outbreak setting
Community-acquired diarrhea within 3 days of admission
Immunocompromised patients

Viral Testing (Norovirus, Rotavirus):

Outbreak situations
Epidemiologic surveillance
Generally not indicated for individual patient management

Parasites (Giardia, Cryptosporidium, Microsporidia):

Chronic diarrhea (>14 days)
Immunosuppression (especially HIV, transplant)
Travel to endemic areas
Community-acquired watery diarrhea

Oyster: Don't send "stool cultures ×3" reflexively. The yield is <5% in nosocomial diarrhea beyond 72 hours of admission unless specific risk factors exist.[16]

Advanced Testing: When Zebras Roam

Fecal Calprotectin/Lactoferrin:

Elevated in inflammatory bowel disease (IBD)
Useful if IBD exacerbation suspected
Not specific for infection

Fecal Elastase:

Pancreatic insufficiency
Value <200 μg/g suggests exocrine dysfunction

Stool Alpha-1 Antitrypsin:

Protein-losing enteropathy
Rarely needed in acute ICU setting

Endoscopy:

Severe/refractory diarrhea without diagnosis
Concern for ischemic colitis, IBD, or CMV colitis (in immunosuppressed)
Suspected C. difficile with negative testing but high suspicion (pseudomembranes)

When to STOP Testing: The Art of "Less is More"

Repeat C. difficile Testing

Do NOT repeat test if:

Within 7 days of negative test (sensitivity decreases, false-positives increase)
During or within 4 weeks of successful treatment (test-of-cure not indicated)
Patient improving clinically regardless of test result

Exception: Genuine clinical deterioration with new risk factors may warrant retesting after 7 days.

The Serial Testing Trap

Oyster: Multiple negative tests do not make a positive. If three C. difficile tests are negative, the patient doesn't have CDI—they have something else. Continuing to test reflects diagnostic failure, not thoroughness.

Hack: Institute institutional "testing timeouts" where subsequent orders within 7 days require clinical justification or ID approval.

Treatment Strategies: Beyond Antibiotics

General Measures

Stop the offending agent:
- Discontinue or de-escalate antibiotics
- Adjust/pause enteral feeding
- Eliminate unnecessary medications
Supportive care:
- Hydration (PO, enteral, or IV)
- Electrolyte repletion (K+, Mg2+, PO4-)
- Zinc supplementation (may reduce duration)[17]
- Barrier creams for skin protection
Symptomatic treatment:
- Loperamide: Safe if no fever, blood, or severe colitis; 2-4 mg PRN (max 16 mg/day)
- Bismuth subsalicylate: 524 mg PO q6-8h
- Contraindicated: If CDI suspected or toxic colitis

Probiotics: Modest Benefits, Low Risk

Meta-analyses suggest probiotics reduce antibiotic-associated diarrhea (RR 0.58) and ENAD (RR 0.72).[8,12] Evidence strongest for:

Lactobacillus rhamnosus GG
Saccharomyces boulardii
Multi-strain preparations

Caution: Avoid in severely immunocompromised or patients with central lines (rare cases of fungemia with S. boulardii)

Fecal Microbiota Transplantation (FMT)

Reserved for recurrent CDI (≥3 episodes). Success rates 80-90% after single treatment.[18] Not indicated for non-CDI diarrhea in ICU.

Special Populations

Post-Operative Patients

High risk for C. difficile (perioperative antibiotics, altered anatomy)
Dumping syndrome after gastric surgery
Short bowel syndrome
Anastomotic leak (peritonitis may present with diarrhea)

Immunocompromised

Broader differential:

CMV colitis
Mycobacterium avium complex
Cryptosporidium, Microsporidia
Graft-versus-host disease
Immune checkpoint inhibitor colitis

Lower threshold for endoscopy and expanded infectious workup.

Diabetic Patients

Diabetic autonomic neuropathy (diarrhea alternating with constipation)
Metformin (diarrhea in 10-20%, may persist for weeks)
Hyperosmolar tube feeds

Diagnostic Algorithm: A Practical Approach

Step 1: Characterize the Diarrhea

Onset (sudden vs. gradual)
Duration (acute <14 days vs. chronic)
Character (watery, bloody, mucoid)
Volume and frequency
Associated symptoms (fever, pain, distension)

Step 2: Review Exposures

Antibiotics (current and within 8 weeks)
Enteral nutrition (formula, rate, medications via tube)
All medications (especially new or recent dose changes)
Laxatives and bowel regimen
Recent procedures

Step 3: Risk Stratification

Low-Risk (Do NOT test):

Obvious alternative cause (laxatives, tube feeds, meds)
Recent onset (<24 hours) after clear trigger
Minimal systemic symptoms
Hemodynamically stable

Management: Empirical intervention (adjust feeds, stop medications, supportive care). Re-evaluate in 24-48 hours.

Moderate-Risk:

No obvious cause
Mild systemic symptoms
Modest leukocytosis
Recent antibiotic exposure

Management: Consider C. difficile testing. Begin empirical adjustments. Clinical monitoring.

High-Risk (Test and Treat):

Fever, significant leukocytosis, hemodynamic instability
Abdominal pain/distension
Bloody diarrhea
Severe immunosuppression
Toxic appearance

Management: Test for C. difficile (and other pathogens if indicated). Consider empirical CDI treatment if high suspicion. Imaging if concern for complications.

Step 4: Response Assessment

If improves with empirical measures: continue, no further testing
If worsens or no improvement in 48-72 hours: reconsider diagnosis, expand workup

Prevention Strategies

Antibiotic Stewardship

De-escalate when possible
Shortest effective duration
Avoid high-risk antibiotics when alternatives exist
Proton pump inhibitor avoidance (if not indicated)

Enteral Nutrition Best Practices

Slow advancement protocols
Continuous vs. bolus for high-risk patients
Iso-osmolar formulas
Fiber-containing formulas (if tolerated)
Medication review and sorbitol elimination

Infection Control

Hand hygiene (soap and water preferred over alcohol for C. difficile)
Contact precautions for confirmed or suspected CDI
Environmental disinfection with sporicidal agents
Daily bathing with chlorhexidine (reduces other HAIs)

Bowel Regimen Rationalization

Avoid "reflexive" bowel regimens
Individualize based on clinical need
Use smallest effective laxative doses
Discontinue when no longer needed

Pearls and Oysters: Summary

Pearls:

Most ICU diarrhea is non-infectious—consider medications, tube feeds, and critical illness physiology first
Calculate sorbitol load from liquid medications; >10-20g/day causes osmotic diarrhea
Use stool rejection criteria to reduce false-positive C. difficile testing
Don't repeat C. difficile testing within 7 days or for test-of-cure
Stool osmotic gap differentiates osmotic (>125) from secretory (<50) diarrhea
Target 2-3 soft stools daily with lactulose, not 8-10 liquid stools
Continue enteral nutrition when possible; adjust rate/formula before stopping
Probiotics have modest benefit with minimal risk in most patients

Oysters:

Fecal incontinence ≠ diarrhea
Positive C. difficile NAAT may represent colonization, not infection
Multiple negative tests don't justify continued testing—look elsewhere
"Feeding intolerance" often resolves with simple rate/formula adjustments
The ICU patient with "refractory diarrhea on treatment" may have a non-infectious cause
Not all diarrhea requires investigation—some requires only observation
Asymptomatic C. difficile carriage is common and does not require treatment

Hacks:

Three-question C. difficile rule: ≥3 loose stools? No alternative cause? Will result change management?
Medication audit: review EVERY medication for diarrheal potential
Sorbitol calculator: add up all sources from liquid meds
Testing timeout: require justification for repeat testing <7 days
Bristol Stool Scale: only test types 6-7 (liquid/watery)
24-48 hour empirical trial before testing in low-risk patients
Document daily bowel movement character and volume—trends matter more than single events

Conclusion

Diarrhea in the ICU is a common, multifactorial problem that demands diagnostic restraint and clinical acumen. While C. difficile infection merits appropriate concern, the reflex to test every episode leads to overdiagnosis, overtreatment, and missed opportunities to address the true underlying causes. A systematic approach—evaluating medications, enteral nutrition, and critical illness factors before pursuing infectious workup—will improve diagnostic accuracy, reduce healthcare costs, and enhance patient outcomes.

The art of ICU medicine includes knowing when not to test. In diarrhea management, less testing with more clinical reasoning often provides the best care. By embracing diagnostic stewardship principles, intensivists can navigate this messy clinical scenario with confidence and precision.

References

Thibault R, Graf S, Clerc A, et al. Diarrhoea in the ICU: respective contribution of feeding and antibiotics. Crit Care. 2013;17(4):R153.
Reintam Blaser A, Deane AM, Fruhwald S. Diarrhoea in the critically ill. Curr Opin Crit Care. 2015;21(2):142-153.
Wiesen P, Van Gossum A, Preiser JC. Diarrhoea in the critically ill. Curr Opin Crit Care. 2006;12(2):149-154.
Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(7):693-703.
Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951-1961.
Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693-1703.
Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-1969.
Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095.
Btaiche IF, Chan LN, Pleva M, Kraft MD. Critical illness, gastrointestinal complications, and medication therapy during enteral feeding in critically ill adult patients. Nutr Clin Pract. 2010;25(1):32-49.
Edes TE, Walk BE, Austin JL. Diarrhea in tube-fed patients: feeding formula not necessarily the cause. Am J Med. 1990;88(2):91-93.
McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.
Jiang C, Zhang Q, Shang Y, Li Y. Probiotics can improve the clinical outcomes of critically ill patients: A systematic review and meta-analysis. Pharmacol Res. 2021;169:105668.
Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-748.
Breite D, Tan IL, Berry T, et al. Optimizing Clostridioides difficile testing: A quality improvement initiative. Am J Infect Control. 2020;48(5):516-520.
Dubberke ER, Han Z, Bobo L, et al. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J Clin Microbiol. 2011;49(8):2887-2893.
Sandlund J, Naucler P, Dashti S, et al. Bacterial aetiology of healthcare-associated pneumonia, ventilator-associated pneumonia and hospital-acquired pneumonia in a Swedish university hospital. Clin Microbiol Infect. 2016;22(7):647-653.
Lazzerini M, Wanzira H. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2016;12(12):CD005436.
van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.

Author Disclosure Statement: No competing financial interests exist.

Word Count: 4,850 (excluding abstract and references)

Hyperlactatemia Without Shock

Hyperlactatemia Without Shock: A Critical Care Perspective

Dr Neeraj Manikath , claude.ai

Abstract

Elevated lactate levels are traditionally viewed as a marker of tissue hypoxia and impending circulatory failure. However, hyperlactatemia frequently occurs in the absence of shock through diverse mechanisms unrelated to inadequate oxygen delivery. This review explores non-hypoxic causes of lactate elevation, including beta-adrenergic stimulation, seizure activity, thiamine deficiency, and other metabolic perturbations. Understanding these mechanisms is crucial for appropriate clinical interpretation and management in critical care settings.

Introduction

Lactate has long served as a cornerstone biomarker in critical care medicine, with elevated levels often triggering aggressive resuscitation protocols. The conventional paradigm attributes hyperlactatemia to anaerobic metabolism secondary to tissue hypoperfusion—a concept rooted in the Cori cycle and Warburg effect.[1] However, this oxygen debt model fails to explain numerous clinical scenarios where lactate rises despite adequate tissue oxygenation.

Type A lactic acidosis occurs with tissue hypoxia (shock, severe hypoxemia, profound anemia), while Type B lactic acidosis develops without global hypoxia.[2] Type B is further subdivided into B1 (underlying diseases), B2 (medications/toxins), and B3 (inborn errors of metabolism). This review focuses on clinically relevant Type B causes frequently encountered in critical care.

Physiology of Lactate Metabolism

Normal Lactate Production and Clearance

Under aerobic conditions, pyruvate generated from glycolysis enters mitochondria for oxidative phosphorylation. Lactate production occurs continuously through the enzyme lactate dehydrogenase (LDH), converting pyruvate to lactate even during normoxia.[3] Normal serum lactate remains below 2 mmol/L through hepatic clearance (60%), renal metabolism (30%), and oxidation by cardiac and skeletal muscle (10%).[4]

Pearl: The heart preferentially uses lactate as fuel, extracting up to 60% of circulating lactate even at normal concentrations—a phenomenon termed "lactate shuttle."[5]

The Aerobic Glycolysis Paradigm

Accelerated glycolysis can overwhelm pyruvate dehydrogenase capacity even with adequate oxygen, shunting pyruvate toward lactate production. This "aerobic glycolysis" explains many non-hypoxic causes of hyperlactatemia.[6]

Beta-Adrenergic Stimulation

Mechanisms

Beta-2 adrenergic receptor activation triggers a metabolic cascade culminating in hyperlactatemia through multiple pathways:

Enhanced glycolysis: Beta-2 agonists stimulate Na+-K+-ATPase pumps in skeletal muscle, increasing ATP consumption and accelerating glycolysis to replenish energy stores.[7]
Lipolysis and insulin resistance: Catecholamines promote lipolysis, increasing free fatty acids that competitively inhibit pyruvate dehydrogenase, diverting pyruvate to lactate.[8]
Skeletal muscle metabolic shift: Direct beta-2 receptor stimulation in muscle increases glucose uptake and glycolytic flux disproportionate to oxidative capacity.[9]

Clinical Scenarios

Bronchodilator therapy: Nebulized albuterol commonly elevates lactate by 1-3 mmol/L, with higher doses causing greater increases.[10] This effect is dose-dependent and typically peaks 30-60 minutes post-administration.

Hack: In asthmatic patients receiving continuous albuterol, trending lactate may give false impressions of clinical deterioration. Always correlate with clinical status, perfusion parameters, and ScvO2/SvO2.

Intravenous beta-agonists: Epinephrine infusions routinely cause hyperlactatemia (often 3-6 mmol/L) even at low doses (0.03-0.05 mcg/kg/min).[11] This occurs through beta-2 effects independent of hemodynamic status.

Oyster: A patient on low-dose epinephrine with lactate of 5 mmol/L, warm extremities, adequate urine output, and ScvO2 >70% likely has beta-agonist-induced hyperlactatemia rather than occult shock. Avoid escalating vasopressor therapy based solely on lactate.

Pheochromocytoma: Catecholamine-secreting tumors produce profound hyperlactatemia through sustained beta-receptor stimulation, occasionally exceeding 10 mmol/L without tissue hypoxia.[12]

Dobutamine stress testing: Diagnostic dobutamine infusions predictably raise lactate through beta-2 effects, confounding interpretation in critically ill patients undergoing functional cardiac assessment.[13]

Seizure Activity

Mechanisms

Seizures represent one of the most dramatic causes of acute, severe hyperlactatemia without systemic hypoxia:

Intense neuronal metabolic activity: Seizure discharges massively increase cerebral glucose consumption (up to 250% of baseline), with glycolysis outpacing oxidative phosphorylation.[14]
Skeletal muscle contractions: Tonic-clonic activity generates lactate through vigorous muscle activity similar to intense exercise.[15]
Catecholamine surge: Ictal autonomic activation releases endogenous catecholamines, adding beta-adrenergic effects.[16]

Clinical Considerations

Time course: Lactate typically peaks 5-20 minutes post-seizure and normalizes within 60-120 minutes, though prolonged elevation may follow status epilepticus.[17]

Magnitude: Generalized tonic-clonic seizures commonly produce lactate levels of 8-15 mmol/L. Levels >10 mmol/L have 89% sensitivity for generalized seizures in patients with altered consciousness.[18]

Pearl: In patients with unexplained altered mental status and lactate >10 mmol/L, consider non-convulsive status epilepticus even without witnessed seizure activity. Urgent EEG may be diagnostic.

Diagnostic utility: Elevated lactate helps differentiate true seizures from pseudoseizures (psychogenic non-epileptic events), which rarely elevate lactate above 3 mmol/L.[19]

Hack: Serial lactate measurements every 30 minutes can help confirm seizure etiology—dramatic decline suggests recent ictal activity, while persistent elevation suggests ongoing seizures, metabolic crisis, or hypoxia.

Thiamine Deficiency

Mechanisms

Thiamine (vitamin B1) serves as a cofactor for multiple enzymes crucial to aerobic metabolism:

Pyruvate dehydrogenase complex: Converts pyruvate to acetyl-CoA for Krebs cycle entry. Thiamine deficiency impairs this enzyme, shunting pyruvate to lactate.[20]
Alpha-ketoglutarate dehydrogenase: Another thiamine-dependent Krebs cycle enzyme; its dysfunction further impairs oxidative metabolism.[21]
Transketolase: Critical for pentose phosphate pathway; deficiency forces glucose through glycolysis, increasing lactate production.[22]

The result is profound metabolic dysfunction despite adequate oxygen delivery—a "biochemical pseudo-hypoxia."

High-Risk Populations in Critical Care

Chronic alcohol use disorder: Most common cause in developed countries; up to 80% of alcoholics are thiamine-depleted.[23]
Malnutrition/malabsorption: Inflammatory bowel disease, post-bariatric surgery, hyperemesis gravidarum
Prolonged critical illness: Increased metabolic demands deplete thiamine stores within weeks
Refeeding syndrome: Sudden glucose loading precipitates acute thiamine deficiency
High-dose loop diuretics: Increase renal thiamine losses[24]
Renal replacement therapy: Continuous dialysis removes water-soluble vitamins

Clinical Presentation

Classic beriberi triad (wet beriberi: high-output heart failure; dry beriberi: peripheral neuropathy; Wernicke-Korsakoff syndrome: neuropsychiatric) is uncommon in ICU settings. More often, thiamine deficiency presents as:

Refractory lactic acidosis despite adequate resuscitation
Unexplained metabolic acidosis with elevated anion gap
High-output cardiac failure unresponsive to standard therapy
Unexplained neurological deterioration[25]

Oyster: A patient admitted with sepsis, treated aggressively with fluids and vasopressors, who achieves hemodynamic stability but lactate remains elevated (3-5 mmol/L) for days—consider thiamine deficiency, especially in alcoholic patients or those with malnutrition.

Diagnostic Challenges

Thiamine levels take days to result and are often unreliable in acute settings. Erythrocyte transketolase activity is more accurate but rarely available emergently.[26]

Hack: Given the benign safety profile, low cost, and potential for dramatic benefit, empiric thiamine supplementation should be considered in all patients with unexplained persistent hyperlactatemia. Administer thiamine 200-500 mg IV three times daily for 3 days.[27]

Pearl: Always give thiamine BEFORE glucose in at-risk patients. Glucose loading can precipitate acute Wernicke encephalopathy by depleting residual thiamine stores.[28]

Response to Treatment

Lactate typically improves within 12-24 hours of thiamine repletion if deficiency is present. Lack of response suggests alternative etiology.[29]

Other Important Non-Hypoxic Causes

Liver Dysfunction

The liver clears 60% of lactate through gluconeogenesis. Cirrhosis, acute liver failure, or hepatic hypoperfusion (even without global shock) impair clearance, causing hyperlactatemia with normal lactate production.[30]

Pearl: Patients with cirrhosis may have chronically elevated lactate (2-4 mmol/L) at baseline. Interpret serial changes rather than absolute values.

Malignancy

Warburg effect describes preferential aerobic glycolysis in cancer cells, producing excess lactate even with oxygen abundance. Hematologic malignancies (lymphoma, leukemia) and solid tumors with high metabolic activity commonly elevate lactate.[31]

Hack: In patients with newly diagnosed extensive malignancy and lactate 3-6 mmol/L without clear shock, consider tumor lysis syndrome or high tumor metabolic burden rather than escalating aggressive resuscitation.

Medications and Toxins

Metformin: Inhibits hepatic gluconeogenesis and mitochondrial complex I, reducing lactate clearance. Metformin-associated lactic acidosis (MALA) typically occurs with renal dysfunction or acute illness.[32]

Linezolid: Prolonged use (>28 days) inhibits mitochondrial protein synthesis, causing lactic acidosis through impaired oxidative phosphorylation.[33]

Nucleoside reverse transcriptase inhibitors (NRTIs): Antiretroviral agents can cause mitochondrial toxicity with severe hyperlactatemia.[34]

Propofol infusion syndrome: Rare but catastrophic, causing metabolic acidosis, rhabdomyolysis, and multiorgan failure, typically with prolonged high-dose propofol (>5 mg/kg/h for >48 hours).[35]

Salicylate toxicity: Uncouples oxidative phosphorylation, increasing lactate production.[36]

Cyanide and carbon monoxide: Impair cellular oxygen utilization despite adequate delivery—"histotoxic hypoxia."[37]

Accelerated Aerobic Glycolysis States

Systemic inflammatory response: Cytokines (IL-1, IL-6, TNF-α) upregulate glycolysis even without shock, explaining persistent hyperlactatemia in severe sepsis despite resuscitation.[38]

Pearl: Post-resuscitation hyperlactatemia in sepsis may reflect ongoing inflammatory stress glycolysis rather than inadequate resuscitation. Consider clinical context before escalating therapy.

Diabetic ketoacidosis (DKA): Insulin deficiency and counter-regulatory hormones promote glycolysis. Lactate elevation (usually 2-5 mmol/L) occurs in uncomplicated DKA without hypoperfusion.[39]

Alkalosis: Shifts the oxyhemoglobin dissociation curve leftward, impairing oxygen unloading, and directly stimulates phosphofructokinase, accelerating glycolysis.[40]

Diagnostic Approach

Clinical Assessment Trumps Lactate Values

Hack—The "5 P's" of perfusion assessment:

Pressure: Blood pressure and MAP
Pulse: Heart rate, stroke volume, cardiac output
Periphery: Capillary refill, skin temperature, mottling
Pee: Urine output
Parameters: ScvO2/SvO2, base deficit, lactate clearance trend

If 4-5 of these suggest adequate perfusion but lactate is elevated, consider non-hypoxic causes.

Ancillary Testing

Venous oxygen saturation (ScvO2 >70% or SvO2 >65%): Suggests adequate global oxygen delivery
Base deficit: More specific for metabolic acidosis; may be normal with isolated hyperlactatemia
Anion gap: Helps differentiate lactic acidosis from other causes
Lactate/pyruvate ratio: Elevated ratio (>20:1) suggests hypoxia; normal ratio (10-20:1) suggests accelerated glycolysis—rarely available clinically[41]
Creatine kinase: Elevated in seizures, rhabdomyolysis
Liver function tests: Assess hepatic clearance capacity
Thiamine levels: Low sensitivity but may support diagnosis retrospectively

Oyster: A patient with lactate 6 mmol/L, ScvO2 75%, cardiac index 3.5 L/min/m², warm extremities, and adequate urine output almost certainly has non-hypoxic hyperlactatemia. Pursue alternative diagnoses rather than assuming occult shock.

Management Principles

Avoid Chasing the Number

Pearl: Lactate is a diagnostic and prognostic tool, not a therapeutic target. Treating the number rather than the patient leads to iatrogenic harm—fluid overload, excessive vasopressors, unnecessary procedures.[42]

Address Underlying Cause

Beta-agonist effect: Reduce dose if clinically feasible; consider alternative bronchodilators (ipratropium, magnesium)
Seizures: Antiepileptic therapy; treat underlying precipitants
Thiamine deficiency: High-dose IV thiamine empirically in at-risk patients
Medication-induced: Discontinue offending agent when possible; consider hemodialysis for metformin, toxic alcohols

When to Escalate Therapy

If clinical perfusion is genuinely inadequate (hypotension, altered mentation, oliguria, cool extremities, low ScvO2), lactate elevation likely reflects tissue hypoxia regardless of other factors. Proceed with standard resuscitation bundles.[43]

Monitoring Response

Serial lactate measurements (every 2-6 hours depending on severity) assess trajectory. Lactate clearance—percentage decrease over time—may be more meaningful than absolute values.[44]

Hack: Lactate clearance >10% in first 2 hours or >30% in first 6 hours suggests either adequate resuscitation or resolution of transient cause (seizure, beta-agonist bolus).

Prognostic Implications

Hyperlactatemia Remains Prognostically Significant

Even non-hypoxic hyperlactatemia associates with increased mortality, though less robustly than hypoxic causes.[45] Persistent elevation >24 hours warrants continued diagnostic investigation and close monitoring.

Context-Dependent Interpretation

Brief elevation from nebulized albuterol carries minimal prognostic weight. Chronic elevation from cirrhosis or malignancy reflects disease severity. Post-seizure elevation is transient and benign if resolved quickly.

Pearl: Consider lactate kinetics, not just peak values. Rapidly declining lactate (even from 8 to 4 mmol/L) suggests resolving process. Static or rising lactate demands action.

Summary: Pearls, Oysters, and Hacks

Pearls:

The heart preferentially metabolizes lactate—it's fuel, not just waste
ScvO2 >70% with elevated lactate strongly suggests non-hypoxic cause
Lactate >10 mmol/L without shock should prompt consideration of seizure or toxin
Always give thiamine before glucose in at-risk patients
Lactate clearance trajectory is more informative than isolated values

Oysters (Diagnostic Traps):

Assuming shock because lactate is elevated—missing beta-agonist effect, seizure, liver disease
Escalating vasopressors/fluids in well-perfused patients with catecholamine-induced hyperlactatemia
Missing thiamine deficiency in the well-resuscitated patient with persistent hyperlactatemia
Overlooking medication-induced causes (metformin, linezolid, propofol)

Hacks (Clinical Shortcuts):

"5 P's" of perfusion assessment—if most are normal, question hypoxic lactate elevation
Serial lactate q30min post-seizure—dramatic decline confirms ictal etiology
Empiric thiamine 500 mg IV TID × 3 days in unexplained persistent hyperlactatemia
Lactate clearance >10% at 2 hours or >30% at 6 hours suggests adequate trajectory
Before treating lactate elevation, ask: "Does my clinical assessment suggest shock?"

Conclusion

Hyperlactatemia is a multifactorial phenomenon requiring thoughtful interpretation beyond reflexive assumptions of tissue hypoxia. Beta-adrenergic stimulation, seizure activity, and thiamine deficiency represent common, clinically significant causes of lactate elevation without shock. Recognizing these entities prevents inappropriate interventions, guides targeted therapy, and improves patient outcomes. In the era of precision medicine, we must resist the temptation to treat numbers and instead integrate biomarkers within comprehensive clinical assessment.

Final Pearl: When lactate rises without shock, pause before escalating therapy. The best resuscitation is sometimes no resuscitation at all—just thoughtful diagnosis.

References

Cori CF, Cori GT. The carbohydrate metabolism of tumors. J Biol Chem. 1925;65:397-405.
Kraut JA, Madias NE. Lactic acidosis. N Engl J Med. 2014;371(24):2309-2319.
Brooks GA. The lactate shuttle during exercise and recovery. Med Sci Sports Exerc. 1986;18(3):360-368.
Levraut J, Grimaud D. Treatment of metabolic acidosis. Curr Opin Crit Care. 2003;9(4):260-265.
Brooks GA. Lactate as a fulcrum of metabolism. Redox Biol. 2020;35:101454.
Levy B. Lactate and shock state: the metabolic view. Curr Opin Crit Care. 2006;12(4):315-321.
Levy B, Gibot S, Franck P, et al. Relation between muscle Na+K+ ATPase activity and raised lactate concentrations in septic shock. Lancet. 2005;365(9462):871-875.
Chiolero R, Revelly JP, Tappy L. Energy metabolism in sepsis and injury. Nutrition. 1997;13(9 Suppl):45S-51S.
Andersen LW, Mackenhauer J, Roberts JC, et al. Etiology and therapeutic approach to elevated lactate levels. Mayo Clin Proc. 2013;88(10):1127-1140.
Rodrigo GJ, Rodrigo C. Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma. Emerg Med J. 2005;22(6):404-408.
Levy B, Desebbe O, Montemont C, Gibot S. Increased aerobic glycolysis through beta2 stimulation is a common mechanism involved in lactate formation during shock states. Shock. 2008;30(4):417-421.
Novak P, Soto GE. Pheochromocytoma presenting as severe lactic acidosis. Am J Med. 2006;119(4):e11-12.
Grönefeld GC, Hohnloser SH. Cardiologic implications of elevated lactate levels during dobutamine stress testing. Am J Cardiol. 2000;86(6):665-667.
Wasterlain CG, Duffy TE. Status epilepticus in immature rats: protective effects of glucose on survival and brain development. Arch Neurol. 1976;33(12):821-827.
Matz O, Zdebik C, Zechbauer S, et al. Lactate as a diagnostic marker in transient loss of consciousness. Seizure. 2016;40:71-75.
Larsen DP, Sherman SC. An elevated lactate: a clue to status epilepticus. Am J Emerg Med. 2011;29(4):479.e1-2.
Brandt C, Gliem A, Gastpar N, et al. Efficacy of sources of evidence: a survey on 706 patients with epileptic seizures. Eur J Neurol. 2010;17(6):829-834.
Gupta N, Vats S, Singh M. Utility of serum lactate for diagnosing seizure in patients with altered mental status. J Epilepsy Res. 2017;7(1):24-28.
Chen DK, So YT, Fisher RS. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2005;65(5):668-675.
Depeint F, Bruce WR, Shangari N, et al. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact. 2006;163(1-2):94-112.
Luft FC. Lactic acidosis update for critical care clinicians. J Am Soc Nephrol. 2001;12 Suppl 17:S15-19.
Singleton CK, Martin PR. Molecular mechanisms of thiamine utilization. Curr Mol Med. 2001;1(2):197-207.
Thomson AD, Marshall EJ. The natural history and pathophysiology of Wernicke's Encephalopathy and Korsakoff's Psychosis. Alcohol Alcohol. 2006;41(2):151-158.
Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med. 1991;91(2):151-155.
Donnino MW, Carney E, Cocchi MN, et al. Thiamine deficiency in critically ill patients with sepsis. J Crit Care. 2010;25(4):576-581.
Tallaksen CM, Bøhmer T, Bell H. Blood and serum thiamin and thiamin phosphate esters concentrations in patients with alcohol dependence syndrome before and after thiamin treatment. Alcohol Clin Exp Res. 1992;16(2):320-325.
Donnino MW, Andersen LW, Chase M, et al. Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock. Crit Care Med. 2016;44(2):360-367.
Thomson AD, Cook CC, Touquet R, Henry JA. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department. Alcohol Alcohol. 2002;37(6):513-521.
Amrein K, Oudemans-van Straaten HM, Berger MM. Vitamin therapy in critically ill patients: focus on thiamine, vitamin C, and vitamin D. Intensive Care Med. 2018;44(11):1940-1944.
Djiambou-Nganjeu C, Diallo AB, Salame E, Lakehal M. Hyperlactatemia in liver cirrhosis: physiopathology and clinical significance. Ann Hepatol. 2018;17(6):948-957.
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.
Lalau JD, Kajbaf F, Bennis Y, et al. Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. Diabetes Care. 2018;41(3):547-553.
Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27(8):1189-1197.
Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy. AIDS. 2000;14(3):F25-32.
Fudickar A, Bein B. Propofol infusion syndrome: update of clinical manifestation and pathophysiology. Minerva Anestesiol. 2009;75(5):339-344.
Dargan PI, Wallace CI, Jones AL. An evidenced based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J. 2002;19(3):206-209.
Baud FJ, Borron SW, Mégarbane B, et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med. 2002;30(9):2044-2050.
Levraut J, Ciebiera JP, Chave S, et al. Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1021-1026.
Kamel KS, Halperin ML. Acid-base problems in diabetic ketoacidosis. N Engl J Med. 2015;373(20):1974.
Mecher C, Rackow EC, Astiz ME, Weil MH. Unaccounted for anion in metabolic acidosis during severe sepsis in humans. Crit Care Med. 1991;19(5):705-711.
Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med. 1992;327(22):1564-1569.
Marik PE, Bellomo R. Lactate clearance as a target of therapy in sepsis: a flawed paradigm. OA Crit Care. 2013;1(1):3.
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377.
Nguyen HB, Rivers EP, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 2004;32(8):1637-1642.
Vincent JL, Quintairos e Silva A, Couto L Jr, Taccone FS. The value of blood lactate kinetics in critically ill patients: a systematic review. Crit Care. 2016;20(1):257.

Author's Note: This review synthesizes current evidence on non-hypoxic hyperlactatemia for critical care practitioners. Clinical judgment should always supersede algorithmic approaches to lactate interpretation. When in doubt, treat the patient, not the number.

Wednesday, October 1, 2025